Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Double Blind, Placebo Controlled, Randomized Study Examining Natrunix in Combination With Standard of Care in HLA-B27 Positive Subjects With Axial Spondyloarthritis

Next Previous
Trial Profile

Phase II, Double Blind, Placebo Controlled, Randomized Study Examining Natrunix in Combination With Standard of Care in HLA-B27 Positive Subjects With Axial Spondyloarthritis

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilamakitug (Primary)
  • Indications Axial spondyloarthritis
  • Focus Therapeutic Use
  • Sponsors XBiotech

Most Recent Events

  • 23 Dec 2024 According to a XBiotech media release, based on phase II study the company has decided to put hold on planned trials of Vilamakitug in rheumatology, including ankylosing spondylitis.
  • 23 Dec 2024 Status changed from not yet recruiting to suspended, according to a XBiotech media release.
  • 02 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top